ATE393627T1 - Wässrige flüssige zubereitung mit 2-amino-3-(4- bromobenzoyl)phenylessigsäure - Google Patents

Wässrige flüssige zubereitung mit 2-amino-3-(4- bromobenzoyl)phenylessigsäure

Info

Publication number
ATE393627T1
ATE393627T1 AT04702854T AT04702854T ATE393627T1 AT E393627 T1 ATE393627 T1 AT E393627T1 AT 04702854 T AT04702854 T AT 04702854T AT 04702854 T AT04702854 T AT 04702854T AT E393627 T1 ATE393627 T1 AT E393627T1
Authority
AT
Austria
Prior art keywords
aqueous liquid
liquid preparation
rhinitis
bromobenzoyl
amino
Prior art date
Application number
AT04702854T
Other languages
English (en)
Inventor
Shirou Sawa
Shuhei Fujita
Original Assignee
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32767329&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE393627(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senju Pharma Co filed Critical Senju Pharma Co
Application granted granted Critical
Publication of ATE393627T1 publication Critical patent/ATE393627T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04702854T 2003-01-21 2004-01-16 Wässrige flüssige zubereitung mit 2-amino-3-(4- bromobenzoyl)phenylessigsäure ATE393627T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003012427 2003-01-21

Publications (1)

Publication Number Publication Date
ATE393627T1 true ATE393627T1 (de) 2008-05-15

Family

ID=32767329

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04702854T ATE393627T1 (de) 2003-01-21 2004-01-16 Wässrige flüssige zubereitung mit 2-amino-3-(4- bromobenzoyl)phenylessigsäure

Country Status (15)

Country Link
US (9) US8129431B2 (de)
EP (1) EP1586316B1 (de)
JP (1) JP4500261B2 (de)
KR (1) KR101059711B1 (de)
CN (1) CN100341498C (de)
AT (1) ATE393627T1 (de)
BE (1) BE2011C027I2 (de)
CA (2) CA2944832C (de)
DE (2) DE122011100019I1 (de)
ES (1) ES2301964T3 (de)
HK (1) HK1083468A1 (de)
HU (1) HUS1100022I1 (de)
MX (1) MX2016014404A (de)
PT (1) PT1586316E (de)
WO (2) WO2004064828A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
WO2004064828A1 (ja) 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
CA2560559C (en) 2004-11-05 2013-07-02 Senju Pharmaceutical Co., Ltd. Aqueous intraocular penetration-promoting eye drop
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
EP1981491A4 (de) * 2006-01-25 2009-09-23 Aciex Inc Formulierungen und verfahren zur behandlung von keratoconjunctivitis sicca
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
WO2008153746A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
CN101313899B (zh) * 2007-06-01 2012-02-29 北京德众万全药物技术开发有限公司 一种含有溴芬酸钠的眼用药物组合物
BRPI0908502A2 (pt) * 2008-02-21 2017-05-23 Ista Pharmaceuticals aines oftálmicos como adjuvantes
KR101541303B1 (ko) * 2008-03-17 2015-08-03 알콘 리서치, 리미티드 보레이트-폴리올 복합체를 함유하는 수성 약학적 조성물
US8778999B2 (en) * 2009-03-05 2014-07-15 Insite Vision Incorporated Non-steroidal anti-inflammatory ophthalmic compositions
TWI489997B (zh) * 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
GB2484843A (en) * 2009-10-15 2012-04-25 Johnson Matthey Plc Polymorphs of Bromfenac sodium
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
AU2010317390A1 (en) * 2009-11-11 2012-06-07 Micro Labs Limited Pharmaceutical combination of prostaglandin compound and NSAID for the treatment of glaucoma and ocular hypertension
CN103379904A (zh) * 2011-01-18 2013-10-30 千寿制药株式会社 具有保存效能的溴芬酸水性液剂组合物
JP6012231B2 (ja) * 2011-04-08 2016-10-25 ロート製薬株式会社 ブロムフェナク含有組成物
US20120276186A1 (en) 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US20130023575A1 (en) * 2011-07-22 2013-01-24 Kamran Hosseini Compositions and methods for the treatment of ocular surface allergies
EP2765988A1 (de) * 2011-10-12 2014-08-20 Bausch & Lomb Incorporated Zusammensetzung für das auge mit bromfenac mit erhöhter bioverfügbarkeit
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
US20130165419A1 (en) * 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
WO2014050301A1 (ja) * 2012-09-27 2014-04-03 千寿製薬株式会社 水性液剤
JP6161500B2 (ja) * 2012-10-05 2017-07-12 ロート製薬株式会社 ブロムフェナク含有組成物
CN104812370B (zh) * 2012-11-19 2018-05-08 博士伦公司 包含2-氨基-3-(4-溴苯甲酰基)苯基乙酸的含水液体组合物
EP2952189B1 (de) * 2013-01-31 2019-09-18 Senju Pharmaceutical Co., Ltd. Klare wässrige lösung
WO2014120293A1 (en) * 2013-01-31 2014-08-07 Sentiss Pharma Pvt.Ltd. Ophthalmic formulations
JP5753957B2 (ja) * 2013-01-31 2015-07-22 千寿製薬株式会社 安定な水性液剤
EA201591910A1 (ru) * 2013-06-19 2016-05-31 Сентисс Рисерч Центр Стабильный раствор бромфенака
WO2015046281A1 (ja) * 2013-09-26 2015-04-02 参天製薬株式会社 安定化された２－アミノ－３－（４－ブロモベンゾイル）フェニル酢酸含有水性組成物
US20170000889A1 (en) * 2013-12-12 2017-01-05 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
CN104151182B (zh) * 2014-06-16 2016-03-30 广东众生药业股份有限公司 一种溴芬酸钠倍半水合物的制备方法
US11452732B2 (en) 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
US10130639B1 (en) 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
CN106404952B (zh) * 2016-08-31 2019-06-11 辰欣佛都药业（汶上）有限公司 一种溴芬酸钠滴眼液有关物质的测定方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2880138A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
US2880130A (en) 1956-12-24 1959-03-31 Upjohn Co Anti-inflammatory steroid solutions
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
JPH0696542B2 (ja) 1987-09-11 1994-11-30 シンテックス（ユー・エス・エイ）インコーポレイテッド 眼用保存製剤およびその製法
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US5414011A (en) 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US4910225A (en) * 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
JPH0283323A (ja) * 1988-09-20 1990-03-23 Zeria Pharmaceut Co Ltd 安定な酪酸リボフラビン水溶液
JPH02124819A (ja) 1988-11-01 1990-05-14 Mitsubishi Kasei Corp 経口コレステロール低下剤
JPH05223052A (ja) 1992-02-06 1993-08-31 Kanematsu Eng Kk 波浪エネルギ−を利用した電流発生装置及びこの電流発生装置が備えられた水素ガス発生装置
DE69328368T2 (de) 1992-08-28 2000-08-10 Pharmos Corp., New York Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge
AU6021794A (en) 1993-01-11 1994-08-15 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
TW358812B (en) 1994-03-15 1999-05-21 Senju Pharma Co Method for stabilizing pranoprofen and a composition and a package thereof
ES2079320B1 (es) 1994-05-17 1996-10-16 Cusi Lab Disolucion oftalmica a base de un diclofenaco y tobramicina y sus aplicaciones.
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
WO1996011003A1 (en) 1994-10-10 1996-04-18 Novartis Ag Ophthalmic and aural compositions containing diclofenac potassium
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US6274592B1 (en) * 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
TW546151B (en) 1997-07-23 2003-08-11 Senju Pharma Co Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative
JPH11228404A (ja) * 1997-12-11 1999-08-24 Senju Pharmaceut Co Ltd 安定な水性点眼剤
US6066671A (en) * 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
US6162393A (en) * 1998-08-06 2000-12-19 Ndt, Inc. Contact lens and ophthalmic solutions
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6369112B1 (en) * 1998-12-15 2002-04-09 Bausch & Lomb Incorporated Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001015677A2 (en) 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Use of 5-ht1b/1d agonists to treat otic pain
EP1213018A4 (de) 1999-09-06 2004-04-14 Ono Pharmaceutical Co Prophylaktische und therapeutische mittel für augenerkrankungen
AR030345A1 (es) 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes relacionados con angiogenesis
JP2002308764A (ja) * 2001-02-09 2002-10-23 Taisho Pharmaceut Co Ltd 眼科用医薬組成物
WO2004064828A1 (ja) * 2003-01-21 2004-08-05 Senju Pharmaceutical Co., Ltd. ２−アミノ−３−(４−ブロモベンゾイル)フェニル酢酸含有水性液剤
CN100551378C (zh) * 2003-11-14 2009-10-21 千寿制药株式会社 包含氨基糖苷类抗生素和溴芬酸的水溶液制剂
EP2765988A1 (de) * 2011-10-12 2014-08-20 Bausch & Lomb Incorporated Zusammensetzung für das auge mit bromfenac mit erhöhter bioverfügbarkeit
CN104812370B (zh) * 2012-11-19 2018-05-08 博士伦公司 包含2-氨基-3-(4-溴苯甲酰基)苯基乙酸的含水液体组合物

Also Published As

Publication number Publication date
MX2016014404A (es) 2017-10-27
US8754131B2 (en) 2014-06-17
EP1586316A1 (de) 2005-10-19
HK1083468A1 (en) 2006-07-07
US20140243413A1 (en) 2014-08-28
US20140235721A1 (en) 2014-08-21
ES2301964T3 (es) 2008-07-01
DE602004013420D1 (de) 2008-06-12
US8871813B2 (en) 2014-10-28
US9144609B2 (en) 2015-09-29
US8669290B2 (en) 2014-03-11
PT1586316E (pt) 2008-05-28
DE602004013420T2 (de) 2009-06-04
EP1586316B1 (de) 2008-04-30
US20140142183A1 (en) 2014-05-22
DE122011100019I1 (de) 2011-11-03
US8497304B2 (en) 2013-07-30
US20120115957A1 (en) 2012-05-10
WO2004064828A1 (ja) 2004-08-05
KR20050092691A (ko) 2005-09-22
US20150011634A1 (en) 2015-01-08
JP4500261B2 (ja) 2010-07-14
CA3043910A1 (en) 2015-11-12
US20150025149A1 (en) 2015-01-22
BE2011C027I2 (de) 2023-03-07
JPWO2004064828A1 (ja) 2006-05-18
CN1700913A (zh) 2005-11-23
US8927606B1 (en) 2015-01-06
CA2944832A1 (en) 2015-11-12
WO2015170177A1 (en) 2015-11-12
US8129431B2 (en) 2012-03-06
CA2944832C (en) 2019-10-08
US9561277B2 (en) 2017-02-07
CN100341498C (zh) 2007-10-10
EP1586316A4 (de) 2007-06-27
HUS1100022I1 (hu) 2017-04-28
US20050239895A1 (en) 2005-10-27
US20070287749A1 (en) 2007-12-13
US20130090384A1 (en) 2013-04-11
KR101059711B1 (ko) 2011-08-29

Similar Documents

Publication Publication Date Title
ATE393627T1 (de) Wässrige flüssige zubereitung mit 2-amino-3-(4- bromobenzoyl)phenylessigsäure
RU2010139958A (ru) Стабилизированная фармацевтическая композиция, cодержащая доцетаксель
CY1118321T1 (el) Συστημα διαλυτων για βελτιωση της διαλυτοτητας των φαρμακευτικων παραγοντων
ATE477283T1 (de) Polymerisierbare zusammensetzungen enthaltend salze aus barbitursäure-derivaten
NO20044406L (no) Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2
DK1605932T3 (da) Intranasal formulering af rotigotin
ATE482700T1 (de) Stabilisierte pharmazeutische zusammensetzung
RU2011101713A (ru) Фармацевтическая композиция
DE602006000874D1 (de) Wässrige Zusammensetzungen enthaltend Salze von Perfluoropolyether Dicarbonsäuren zur ölabstossenden Papierleimung
JP2009178558A5 (de)
DK1853279T3 (da) Amid-derivater af hyaluronsyre i osteoarthrose
ATE442849T1 (de) Wässrige zusammensetzung mit einem thiazol- derivat
FR2933006B1 (fr) Solution absorbante contenant un inhibiteur de degradation soufre a groupement carboxyle et methode pour limiter la degradation d'une solution absorbante
AR063027A1 (es) Derivados de sulfonamida
EA200501789A1 (ru) Стабильный водный раствор эритропоэтина человека, не содержащий сывороточного альбумина
DK1459739T3 (da) Ikke-hydroskopiske farmaceutiske sammensætninger indeholdende ikke-hydratiserede quinolin-carboxylsyrer
EA201490127A1 (ru) Офтальмологический раствор, содержащий гиалуроновую кислоту или ее соль и пропиленгликоль
CY1112285T1 (el) Υγρες φαρμακοτεχνικες μορφες αλατων 4-[2-(4-μεθυλφαινυλσουλφανυλ)φαινυλ]πιπεριδινης
DE602004009573D1 (de) Herstellung von 5-methyl-dihydrofuran-2-on aus levulinsäure in superkritischen medien
MA30600B1 (fr) Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique.
WO2015087267A3 (en) Stable bromfenac ophthalmic solution
EA201591910A1 (ru) Стабильный раствор бромфенака
EP2494955A3 (de) Stabile flüssige pharmazeutische Zusammensetzung basierend auf Trazodon
BRPI0814580A2 (pt) Utilização de pelo menos um derivado de oxima da colest-4-en-3-ona ou um dos seus sais de adição com ácidos aceitáveis, ou de um dos seus ésteres ou de um dos sais de adição dos referidos ésteres com os ácidos aceitáveis
EA200800150A1 (ru) Состав с пролонгированным высвобождением действующих начал лекарственного средства